On April 29, Yanan Bicon Pharmaceutical Listed Company(002411) announced that due to the failure to reach an agreement with the annual report audit institution on major matters, the company encountered difficulties in the preparation of periodic reports and was unable to disclose the annual report of 2021 and the first quarterly report of 2022 within the legal period.
Yanan Bicon Pharmaceutical Listed Company(002411) was originally scheduled to disclose the annual report of 2021 and the first quarterly report of 2022 on April 27. Previously, it has applied for an extension to April 30. Now it is clear that it is impossible to disclose relevant periodic reports within the legal period, and the trading of the company will be suspended from the next trading day (i.e. May 5) after the expiration of the disclosure period of the annual report in 2021.
According to the follow-up process, if Yanan Bicon Pharmaceutical Listed Company(002411) is still unable to disclose the 2021 annual report within two months of stock suspension, the Shenzhen Stock Exchange will implement delisting risk warning for its stock trading; If the listed company fails to disclose the true risks of the listed shares and withdraw from the Shenzhen Stock Exchange within two months after the implementation of the annual report in 2021, more than half of the listed shares may be terminated.
Yanan Bicon Pharmaceutical Listed Company(002411) said that the company is making every effort to promote the preparation of the 2021 annual report and the first quarterly report of 2022, strengthen the communication with the annual audit accountant and other relevant parties, speed up the preparation and review of the periodic report, and strive to disclose the 2021 annual report and the first quarterly report of 2022 within two months from the expiration of the statutory disclosure period.
